Class 4 caution in use-Topiramate 20mg/ml oral solution

Zydus Pharmaceuticals UK LTD has informed the MHRA that there is an error on the artwork for the outer carton and Patient Information Leaflet (PIL) of Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution (pack size 150ml and 280ml bottles).

MHRA drug alert link:Class 4 Medicines Defect Notification: Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution, Zydus Pharmaceuticals UK Ltd, EL(25)A/39 - GOV.UK

MHRA drug alert date:07/08/25

This is a caution in use only we are not accepting stock returns

Further Information

For all enquires on this product please email DrugSafety@ZydusUK.com or telephone 0800 9956034.

Class 2 recall-Fucidin 250mg tabs

LEO Pharma is recalling the affected batch as a precautionary measure due to out of specification results for impurities during routine stability testing.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-fucidin-250-mg-tablets-leo-laboratories-ltd-trading-as-leo-pharma-el-25-a-slash-38

MHRA drug alert date: 02/08/25

Further Information

For all enquiries and information on this product, please email medical-info.uk@leo-pharma.com or telephone 01844 347 333 and press 2 for Medical Information.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

August 2025 bank holiday opening hours

To help keep our customers informed of changes to our service, we have published our August 2025 bank holiday opening hours for pharmacy and retail customers.

August 2025 bank holiday opening hours

August 2025 bank holiday opening hours (for Channel Islands and Isle of Man)

Class 4 Caution in use-Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals

Jubilant Pharmaceuticals NV has informed the MHRA that the Patient Information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.

MHRA drug alert link:Class 4 Medicines Defect Notification: Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals NV, EL(25)A/37 - GOV.UK

MHRA drug alert date:31/07/25

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please email safety.uk@lambda-cro.com, or telephone  0800 0668348.

For stock control enquiries please email JPUK.Customerservice@jubl.com, or telephone 01233 552293

Class 2 recall-Flutiform 250/10mg (Alliance healthcare do not stock)

CD Pharma Ltd have notified the MHRA of an error on the outer carton of the product for the batches listed in this notification. While the total active content statement is correct, the delivered dose content statement is incorrect. The other details on the carton are correct.

Drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-flutiform-250-micrograms-slash-10-micrograms-per-actuation-pressurised-inhalation-suspension-cd-pharma-ltd-el-25-a-slash-35?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=a726e5d4-c8e3-40a1-8762-ec99de3f74bb&utm_content=immediately

drug alert date: 24/07/25

Further Information

For all further enquiries please contact 01355 204 448 or email regaffairs@teleta.co.uk

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Cencora Teams Raise £15,000 for Charity in Race the Sun Challenge!

Race the Sun Cheddar Gorge Challenge 2025 ☀️

Teams from Cencora Alliance Healthcare and Cencora Alloga have successfully raised and donated £15,000 for Action Medical Research following the Race the Sun Cheddar Gorge Challenge 2025 involving 30 team members from across the business. 

Participants pushed their limits in a day-long challenge involving:

    - 30 mile cycle (2,000 feet elevation) 🚴

    - 6 mile hike (1,200 feet elevation) 🚶

    - 1.2 mile canoe 🛶

All in the breathtaking surroundings of Cheddar Gorge in Somerset! On an extremely hot day (33.C) – really feeling the sun in the Race the Sun Challenge. All team members completed safely and were determined to reach the finish line to support vital medical research that saves children’s lives.

Action Medical Research is the UK’s leading charity dedicated to funding research to help sick and disabled babies, children and young people. For over 70 years, the charity has played a crucial role in driving medical progress, supporting research into rare and complex conditions that often receive little funding. The charity’s research has helped develop both the polio vaccine and ultrasound scanning in pregnancy, changing lives worldwide. 

Sam Unsworth, Head of Communications and RTS Challenger at Alliance Healthcare, said: “It was amazing to be part of a day filled with such strong team spirit and shared purpose. We’re so proud to be contributing to research that’s making a real difference for children and their families.” 

Lucy Holloway, Corporate Partnership and Event Management Executive, Action Medical Research said: “We are immensely grateful for the continued support of Alliance Healthcare UK. The funds that have been raised will go a long way in facilitating change for these children’s lives through important medical research.” 

The Race the Sun Cheddar Gorge Challenge 2025 showcased not only the physical endurance of the Alliance Healthcare and Alloga team members, but also the unwavering commitment to building a community united in supporting healthier futures through charitable fundraising and collective action. 

Class 2 recall-Zaditen eye drops

Laboratoires Théa trading as Thea Pharmaceuticals Limited have notified the MHRA of an out of specification event related to environmental monitoring during manufacturing, which may increase the risk of microbial contamination of the medicinal product.

Drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zaditen-0-dot-25-mg-slash-ml-eye-drops-solution-laboratoires-thea-el-25-a-slash-34

drug alert date: 4/07/25

Further Information

For stock control enquiries please contact:

• For pharmacies supplied by a wholesaler, returns should be made via the wholesaler.
• For wholesalers, please contact Mawdsleys PreWholesaler (MPW) customer services using e-mail address customer.services@mpwpharma.co.uk
• For healthcare establishments: please arrange local destruction and make a claim through Mawdsleys PreWholesaler customer.services@mpwpharma.co.uk

For more information or medical information please call 0345 521 1290 (and select option 3) or e-mail thea-pharma@medinformation.co.uk

For stock control enquiries please email customer.services@mpwpharma.co.uk

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Simvastatin 10mg Tablet, Crescent Pharma Ltd

Crescent Pharma Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of simvastatin 10 mg Tablets distributed by Alliance Healthcare UK.

MHRA Drug alert link: Class 4 Medicines Defect Notification: Simvastatin 10mg Tablet, Crescent Pharma Ltd, EL(25)A/33 - GOV.UK

MHRA drug alert date: 3/07/25

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email medinfo@crescentpharma.com, for reporting of side effects email safety@crescentpharma.com or telephone +44 1217901596.

For stock control enquiries please email Sean.McCaul@alliance-healthcare.co.uk

Class 4 caution in use-Erythromycin Stearate BP 250mg Tablets

Amdipharm UK Ltd has informed MHRA that the Patient information leaflet (PIL) in the cartons for the batch listed in this notification includes a superseded PIL.

MHRA Drug alert link: Class 4 Medicines Defect Notification: Erythromycin Stearate BP 250mg Tablets, Amdipharm UK Ltd, EL(25)A/32 - GOV.UK

MHRA drug alert date: 1/07/25

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please email medicalinformation@advanzpharma.com, or telephone +44 (0) 208 588 9131

For stock control enquiries please email custcustomercare@advanzpharma.com or telephone 0208 588 9441

Class 3 recall-Tamoxifen 20mg Film-Coated Tablets

Wockhardt UK Limited is recalling a batch as a precautionary measure following the identification of a dissolution failure during stability testing.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-tamoxifen-20mg-film-coated-tablets-wockhardt-uk-ltd-el-25-a-slash-31?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=51a03b30-994a-4270-a2ee-77e56b55fcd8&utm_content=immediately

MHRA drug alert date: 30/06/25

Further Information

For medical information enquiries please email drug.safety@wockhardt.co.uk, or telephone 01978 661261 and ask for ‘drug safety’.

For stock control enquiries please email group_uk_csu@wockhardt.co.uk, or telephone 01978 661261and ask for ‘customer services’.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.